Is CSBR or CTMX more undervalued in 2026?

CirclFi compares Champions Oncology, Inc. (CSBR) and CytomX Therapeutics, Inc. (CTMX) using 13 institutional-grade valuation models. CSBR has a Quality of Company score of 8.1/10 while CTMX scores 6.7/10.

Which is a better buy — CSBR or CTMX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CSBR and CTMX valuations compare?

CSBR at $5.85 and CTMX at $3.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CSBR vs CTMX Valuation Comparison 2026 — Intrinsic Value Analysis

CSBR

Biotechnology

Champions Oncology, Inc.

Quality

8.1

out of 10

Value Trap

—

Price

$5.85

Last close

Models

12/13

Active

CTMX

Biotechnology

CytomX Therapeutics, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$3.71

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CSBR Fair Value	CSBR Upside	CTMX Fair Value	CTMX Upside
Bayesian DCF	Intrinsic	$1.79	-69.4%	$0.80	-78.4%
Earnings Power Value	Intrinsic	$0.36	-93.8%	$0.37	-90.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CSBR vs CTMX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CSBR vs CTMX — Which Stock Is More Undervalued?

CSBR scores higher with a 8.1/10 quality rating vs CTMX's 6.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Champions Oncology, Inc. (CSBR) and CytomX Therapeutics, Inc. (CTMX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CSBR currently trades at $5.85 with a QOC of 8.1/10, while CTMX trades at $3.71 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).